z-logo
open-access-imgOpen Access
The potency of Pentagamavunone‐0 (PGV‐0) as chemopreventive agent for the formation and growth of breast cancer as revealed in 3D model
Author(s) -
Wulandari Wulandari,
Muthi Ikawati,
Edy Meiyanto
Publication year - 2020
Publication title -
indonesian journal of biotechnology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.173
H-Index - 2
eISSN - 2089-2241
pISSN - 0853-8654
DOI - 10.22146/ijbiotech.51759
Subject(s) - potency , breast cancer , cancer , mcf 7 , cytotoxic t cell , spheroid , growth inhibition , cancer cell , ic50 , cell culture , mtt assay , cancer cell lines , cell growth , cancer research , chemistry , medicine , biology , in vitro , human breast , biochemistry , genetics
Pentagamavunone‐0 (PGV‐0) or 2,5‐bis(4’‐hydroxy‐3‐methoxybenzylidine)‐cyclopentanone is a curcumin analogue that exhibits anticancer activity in breast cancer cells. However, most of previous reports are limited to the use of two‐dimensional (2D) cell culture. The use of three‐dimensional (3D) cell culture model in cancer research can represent the real condition of cancer growth in patients better than the 2D culture. The purpose of this study was to determine the anticancer activity of PGV‐0 on a 3D model of HCC 1954 breast cancer cells. HCC 1954 cells were grown in the 3D culture in the presence of PGV‐0, and the spheroid formation and growth of formed spheroids were observed using microscope at 24 and 96 h, respectively. The cytotoxic effects were measured by MTT assay. PGV‐0 inhibited the formation and growth of spheroids at the concentration as low as 60 µM. The cytotoxic effect of PGV‐0 appeared in a dose‐dependent manner with the IC50 value of 70.9 µM. The results of this study indicate that PGV‐0 has an anticancer activity on a 3D model of HCC 1954 breast cancer cell line. Therefore, the result supported the potency of PGV‐0 as cancer chemopreventive agent.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here